Supplementary legends, "Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study"

Supplemental Fig 1. An overview of study design. The recommended doses regimen is 160 mg at the first administration and then 80 mg at week 2, 4, 6, 8,10, and 12, followed by monthly maintenance dosing. The adjusted doses regimen is 160 mg at the first administration and then 80 mg at week 2, 4 and 8, followed by maintenance dosing every 8 weeks. Only one patient discontinued IXE treatment due to the treatment-unrelated cause which was the recurrence of lung cancer. 29, 20, 9 and 2 patients simply entered the study too late to make it to 32, 24, 16 and 8 weeks by the end of the study, respectively. Supplementary Fig 2. Changes of PASI before and after receiving IXE in different weeks. Evaluations of Changes of PASI were assessed by physicians during follow-up in patients with psoriasis. The Wilcoxon signed-rank test was used to compare matched values. Supplementary Table 1. Adverse events of total patient population. Data are expressed as absolute number (percentage).